Brief: Ose Immunotherapeutics To Continue Clinical Development In Ulcerative Colitis With Full Rights To Lusvertikimab
12/05/2023 19:06
May 12 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS TO CONTINUE THE CLINICAL DEVELOPMENT IN ULCERATIVE
COLITIS WITH FULL RIGHTS TO LUSVERTIKIMAB
* OSE IMMUNOTHERAPEUTICS SA - TOP LINE RESULTS IN INDUCTION PHASE DECEMBER
2023
* OSE IMMUNOTHERAPEUTICS SA - FIRST EARLY MAINTENANCE DATA AFTER 6 MONTHS OF
TREATMENT: H1-2024
Source text for Eikon: ID:nBw74pgCGa
Further company coverage: OSE.PA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO